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Abstract: Reactive oxygen species (ROS) play an important role in cell proliferation and differen-
tiation. They are also by-products of aerobic living conditions. Their inherent reactivity poses a
threat for all cellular components. Cells have, therefore, evolved complex pathways to sense and
maintain the redox balance. Among them, Nrf2 (Nuclear factor erythroid 2-related factor 2) plays a
crucial role: it is activated under oxidative conditions and is responsible for the expression of the
detoxification machinery and antiapoptotic factors. It is, however, a double edge sword: whilst
it prevents tumorigenesis in healthy cells, its constitutive activation in cancer promotes tumour
growth and metastasis. In addition, recent data have highlighted the importance of Nrf2 in evading
programmed cell death. In this review, we will focus on the activation of the Nrf2 pathway in
the cytoplasm, the molecular basis underlying Nrf2 binding to the DNA, and the dysregulation of
this pathway in cancer, before discussing how Nrf2 contributes to the prevention of apoptosis and
ferroptosis in cancer and how it is likely to be linked to detoxifying enzymes containing selenium.
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1. Introduction
Reactive oxygen species (ROS) are small molecules that play important roles as me-
diators in cell signalling, proliferation, and differentiation [1]. They are generated during
oxidative phosphorylation and metabolism, leading to ATP synthesis. Hydroxyl radical
(HO•), hydrogen peroxide (H2O2) and superoxide anion (O2•−) are some examples of such
molecules. ROS can also be generated by external factors (e.g., xenobiotic compounds and
pollution) [1].
ROS are extremely reactive: they can damage lipids, nucleic acids and proteins.
Lipid peroxidation is a chemical reaction occurring on polyunsaturated fatty acids that is
particularly harmful to cells. Not only does it cause changes in membrane permeability
and fluidity, it also creates a chain reaction that simply increases cellular ROS levels in
the cells. Cells are particularly sensitive to this type of damage, and possess a specific cell
death program, ferroptosis, associated with lipid peroxidation. Nucleic acids are sensitive
to ROS: they can cause mutations and double strand breaks, threatening genome stability.
Proteins can be oxidized, and their co-factors can be damaged or lost, all of which leads to
impaired activity. This reactivity can be harnessed by cells to defend against pathogenic
infection [2].
ROS are both ubiquitous by-products of our aerobic living conditions and potentially
harmful molecules. Therefore, cells have evolved complex pathways to sense and maintain
the redox balance or ‘redox homeostasis’. Failure to maintain this can lead to pathological
conditions: ROS are implicated in several human conditions, from carcinogenesis [3] and
neurodegeneration [4] to aging [5]. Redox homeostasis is maintained by a large array of
enzymes that regulate detoxification. Superoxide dismutase hydrolyses O2•−, catalase and
glutathione peroxidase [6] degrade H2O2, and the thioredoxin pathway reduces oxidised
proteins [7].
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Several pathways are able to sense the redox balance and activate transcription of
the detoxification machinery [8]. Among them, the transcription factor Nrf2 (Figure 1)
is particularly important because it can be directly activated by ROS [9] and leads to the
expression of the phase II detoxifying enzymes. In fact, Nrf2 (Nuclear factor erythroid
2-related factor 2) is located at the nexus between ROS signalling, endoplasmic reticulum
(ER) stress response [10], metabolism [11], and autophagy [12]. It is therefore not surprising
that Nrf2 target genes are involved in the antioxidant system (enzymes and co-factors),
xenobiotic detoxification metabolism and excretion, DNA damage response, autophagy
and antiapoptotic factors [13].
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tain several reactive cysteines. (C) sMaf proteins are the obligate heterodimers that are required for Nrf2 to bind the DNA. 
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domain that interacts with other bZIP and CNC transcription factors. (D) Bach1 also belongs to the cap’n’collar transcrip-
tion factor family. It contains a BTB domain that allows protein/protein interactions, and a CNC domain. Additionally, it 
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Nrf2 is constitutively bound by the ubiquitin ligase Keap1-Cul3-Rbx1 [9] and targeted for 
proteosomal degradation. In this respect, Keap1 serves as a protein adaptor between Nrf2 
and the E3 ligase. In addition, it contains several redox sensitive cysteines that modulate 
the conformation and activity of the complex [16]. Indeed, under oxidative conditions, the 
complex is inactivated and inhibits the degradation of the transcription factor. Newly syn-
thesised Nrf2 molecules can translocate into the nucleus and express genes under its con-
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Figure 1. Domain representation of Nrf2, Keap1, sMaf proteins and Bach1. (A) Nrf2 contains a Neh2 domain that is
ubiquitinated by Keap1-Cul3-Rbx1 E3 ubiquitin ligase complex. Nrf2 is recruited in the complex by the DLG and ETGE
motifs flanking the Neh2. The domains Neh4 and 5 are transactivation domains, while the Neh6 domain is phosphorylated
by Gsk3 (glycogen synthase kinase-3) and targeted for degradation by βTrcP. The Neh1 domain is the cap’n’collar bZIP
domain, required for the interaction with sMaf proteins and DNA binding. (B) Keap1 contai s a BTB domain required to
recruit Cul3, the IVR domain that contributes to these int ract ons, and Kelch repeats that interact with Nrf2. Keap1 contain
several reactive cysteines. (C) sMaf proteins are the obligate heterodimers that are required for Nrf2 to bind the DNA.
They belong to the bZIP family of transcription factors. They contain a basic region that binds the DNA and leucine zipper
domain that interacts with other bZIP and CNC transcription factors. (D) Bach1 also belongs to the cap’n’collar transcription
factor family. It contains a BTB domain that allows protein/protein interactions, and a CNC domain. Additionally, it
contains heme binding sites that regulate its binding on the DNA.
Nrf2 is regulated at the protein level by several ubiquitin ligases [9–11] and by post-
translational modification [14,15]. In the canonical pathway and under basal conditions,
Nrf2 is constitutively bound by the ubiquitin ligase Keap1-Cul3-Rbx1 [9] and targeted for
proteosomal degradation. In this respect, Keap1 serves as a protein adaptor between Nrf2
and the E3 ligase. In addition, it contains several redox sensitive cysteines that modulate
the conformation and activity of the complex [16]. Indeed, under oxidative conditions,
the complex is inactivated d inhibits the degradation of the transcription factor. Newly
synthesised Nrf2 molecules can translocate into the nucleus and express genes under its
control.
Nrf2 belongs to the Cap’n’collar bZIP transcription factor family (Figure 1). In order
to bind the DNA, it requires heterodimerisation with sMaf proteins. Their association in
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the promoter region of target genes recruits co-activators including CBP/P300, an acetyl-
transferase that can modify histones and transcription factors [17]. Histone acetylases
are required to recruit the transcriptional machinery and relax the chromatin prior to
its opening for transcription initiation. However, CBP/P300 (cAMP regulated enhancer
binding protein) can also acetylate Nrf2 to increase (i) expression of the target gene [18]
and (ii) the sequence specificity [19]. Interestingly, the recruitment of co-activators seems
to be gene-specific: BAF190A, part of the PBAF chromatin remodeler, is specifically re-
cruited at heme oxygenase 1 gene, but not NADPH:quinone oxidoreductase 1 [20]. Finally,
Nrf2 can interact directly with Med16, a subunit of the Mediator complex, to recruit the
transcriptional machinery [21].
Upon integration of different stresses, Nrf2 activation leads to the transcription of
cytoprotective and antiapoptotic genes. In this regard, Nrf2 has long been considered as
beneficial to protect cells against ROS damage, to help them to recover after a stress and
to catabolise/excrete xenobiotic molecules. This requires tight control and regulation of
the pathway. In fact, growing evidence suggest that activation of the pathway in cancer
can have deleterious effects because Nrf2 acts directly or indirectly on all the hallmarks of
cancer [13]. In cancer, the inherent higher ROS levels -presumably due to higher metabolism
and the Warburg effect- lead to a constitutive activation of the pathway; and the same anti-
apoptotic factors promote tumour growth and metastasis. The inherent higher tolerance
to oxidative stress confers radio-resistance, and the xenobiotic transporters confer chemo-
resistance, so that patients with cancer who have the Nrf2 pathway activated have a
poor prognosis. These roles are referred to as the “dark side of Nrf2” [22]. Importantly,
the mechanisms switching off Nrf2 in cancer cells, e.g., cell death programs, are also
deregulated.
Some detoxifying enzymes under the control of Nrf2 are seleno-containing proteins.
Selenium is a trace element that enters in the composition of some proteins, where it is
present as selenomethionines (SeMet) and selenocysteines (SeCys). This class of proteins
is called selenoprotein. SeCys, the 21st amino acid, is found in the three kingdoms of
life but is absent in yeast, fungi and higher plants. The Human proteome contains 25
selenoproteins [23], where they are largely involved in redox regulated processes, ER stress
response and calcium homeostasis. However, the function of several of them remains
elusive [24]. The selenol (-SeOH) function of selenocysteine has a lower pKa (about
5.2) than cysteines (about 8.0), which makes them particularly reactive. This aspect is
particularly important in respect of their activity in the oxidative stress response: two
families of detoxifying enzymes, glutathione peroxidase [6] and thioredoxin reductase [25],
contain a selenocysteine in their active sites. In fact, some of these detoxifying enzymes
that are regulated by the oxidative stress themselves regulate the redox homeostasis and
are implicated in cancer.
In this manuscript, we will review the basic mechanisms underlying Nrf2 activation
in the cytoplasm as well as the recruitment of Nrf2 at its promoter. We will detail the in-
volvement of Nrf2 in cancer development. Finally, we will discuss the latest developments
in the involvement of seleno-containing detoxifying enzymes in cell death programs.
2. Regulation of Nrf2 in the Cytoplasm
Nrf2 factor can be activated by different pathways. In this paragraph, we will review
the different mechanisms regulating Nrf2.
2.1. Nrf2-Keap1-Cul3 Ubiquitin Ligase, the Canonical Pathway
The transcription factor Nrf2 is tightly regulated to ensure it only activates transcrip-
tion of downstream antioxidant proteins in times of cellular oxidative stress. The major
regulator of Nrf2 is the substrate adapter protein Keap1 which specifically targets Nrf2
to the E3 ubiquitin ligase complex. Keap1 (Kelch ECH-associating protein 1, Figure 1) is
part of the cullin3-depedent E3 ubiquitin ligase complex which ubiquitinates Nrf2 in the
cytoplasm targeting it for degradation by the 26S proteosome. We invite the reader to
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consult the review “structural basis of Keap1 interactions with Nrf2” for more details [26].
Under basal conditions, Nrf2 is maintained at a low cellular concentration by Keap1 ac-
tivity. This allows for low levels of expression of Nrf2 regulated genes to maintain redox
homeostasis [27,28].
Keap1 specifically interacts with two particular sequences of Nrf2 docking it for
ubiquitination by the E3 ligase complex. Interactions with Keap1 occur within the Neh2
domain of Nrf2 with the Kelch domain of Keap1 (Figures 1 and 2) [29]. The specific
interactions between Keap1 and Nrf2 are central to the targeting of Nrf2 for ubiquitination
and the regulation of Nrf2 during times of oxidative stress. Two amino acid regions within
the N-terminal Neh2 domain of Nrf2 form two patches that interact with the Keap1 Kelch
domain. The two motifs, ETGE and DLG, have different binding affinities for Keap1. The
ETGE exhibits a slow rate of association and dissociation with a strong binding affinity
compared with the DLG domain, which binds faster but with a lower binding affinity. It is
hypothesised that the high affinity ETGE acts as a hinge, anchoring Nrf2 onto the Kelch,
domain whereas the DLG acts as a latch; modifications to Keap1 in response to oxidative
stress may prevent the latch attaching, reducing the regulatory effects that Keap1 has on
Nrf2 [29,30]. This mechanism is referred to as “hinge and latch” mechanism. However, a
recent report contradicts this process. Horie et al. employed NMR spectroscopy to assess
the binding of labelled Neh2 domain to Keap1 [31]. The authors did not observe latch
dissociation upon treatment with known electrophiles. Even if one of the compounds used
was known to dissociate cullin3 (Cul3) from Keap1 [32], the others did not show this effect
in previous studies [32]. The molecular mechanism underlying ubiquitination inhibition
by electrophiles requires more investigation (Figure 2).
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Figure 2. Canonical activation of the Nrf2 pathway. Nrf2 is constitutively bound by Keap1 through the DLG and ETGE
motifs that serve as hinge and latch. Keap1 interacts with Cul3/Rbx1 and targets Nrf2 for proteosomal degradation. Under
oxidative conditions, Keap1 ca be modified at critical cysteines highlighted by a star. This inactivates the ubiquitin ligase
comp ex by either dissociating Cul3 or a ye to be discovered mechanism. P62 ca compete with the DLG motif of Nrf2
following the hinge and latch mechanism, thereby preventing ubiquitination. The newly synthesised Nrf2 molecules can
translocate into the nucleus where they bind the CsMBE sequences with sMaf proteins. Nrf2 can be acetylated by CBP/P300
to increase the sequence specificity and transcriptional output. Nrf2, acetylated or not, recruits the Mediator complex and
the RNA polymerase II transcriptional machinery.
Keap1 assembles as a homodimer through their BTB domains (Figures 1 and 2)
into a stable and functional E3 ubiquitin ligase complex with Cul3 and Rbx1 proteins.
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Early reports suggested that the ubiquitin ligase complex contains two Keap1 for one
Cul3/Rbx1 [33], but other works suggest a 2:2 complex [34,35]. There are a number of
cullin-ring ligases (CRLs) comprised of different cullin proteins and substrate adapter
proteins which are essential due to their ability to covalently modify proteins to alter their
abundance and function [36]. The lysine residues targeted for poly-ubiquitination in Nrf2
are found in close proximity to the Keap1 interacting domains in the Neh2 domain [27]. Tar-
get proteins have degradation signals known as N-degrons and C-degrons situated at the
N- and C-terminal of the substrate protein, respectively. These sequences contain adjoining
sequence motifs with internal lysine residues primed for ubiquitination when exposed [37].
Nrf2 has an N-degron commonly found in short-lived proteins where Keap1 is able to
recognise and bind Nrf2 priming the lysine residues for covalent attachment of ubiquitin.
The precise mechanism of poly-ubiquitination remains to be understood at the molecular
level, but what is clear is that proteasome targeting requires p97 to release Nrf2 from the
ubiquitin ligase complex [38] (Figure 2). Ubiquitination is extensively studied but remains
to be fully understood. For example, the roles of the possible redundant ubiquitination
sites of Nrf2 remain to be clarified, as well as the stoichiometry of the complex.
Under conditions of oxidative stress, Keap1 repression of Nrf2 is prohibited. This
allows Nrf2 to translocate into the nucleus and accumulate where it is free to activate
transcription of antioxidant proteins to deal with the increased level of ROS [39]. The easing
of repression by Keap1 relies on the ability of Keap1 to act as a redox sensor. This is achieved
by the presence of several sensitive cysteine residues that are vulnerable to oxidation by
electrophiles in the cell. These residues include cysteines at positions 155, 226, 272, 288, 434,
613 and particularly cysteine 151 (Figures 1 and 2). They are critical in the regulation of Nrf2
and each respond to different oxidants, leading to the concept of a cysteine code [26,40].
Itaconate, a small molecule released by the mitochondria under reperfusion, has been
shown in cells to react with C151 and activate the Nrf2 pathway [41]. It has been shown
that a Keap1 mutant lacking 11 cysteine residues, including the ones mentioned here, is
unable to respond to reactive oxidative inducers that signal for Nrf2 activation. However,
these cysteine residues are not required to target Nrf2 for degradation [40]. Cysteine
modifications to Keap1 during oxidative stress are thought to alter the conformation of the
Cul3-Keap1-Rbx1 complex, resulting in the impaired assembly of Nrf2 into the complex
and subsequent failure to ubiquitinate Nrf2. Prolonged exposure of Keap1 to oxidative
stress is also thought to result in further modifications to Keap1 that expose lysine residues
for its own ubiquitination [36]. Unlike ubiquitination of Nrf2, Keap1 is tagged at position
lysine 63 and therefore is not targeted for proteosome degradation. Furthermore, cullin-
ring ligases can be subject to auto-ubiquitination, which may be necessary to regulate levels
of Nrf2 to sustain the antioxidant response over time [36].
Under basal cellular conditions, the Keap1 complex is the major regulator present in
the cytosol turning over Nrf2 protein. Keap1 regulation of Nrf2 also occurs in the nucleus
postinduction by assisting its nuclear export [42], effectively turning off Nrf2 dependent
transcription.
2.2. Other Pathways Regulating Nrf2 Levels and Cellular Localisation
Nrf2 has also been shown to be regulated by the substrate receptor β-transducin
repeat-containing protein (β-TrCP) [43]. β-TrCP is the substrate recognition subunit for
the E3 ubiquitin ligase complex, Skp1-Cul1-Rbx1. This complex specifically targets phos-
phorylated substrates and are essential in regulating cell division and signal transduction
and subsequently they are prevalent in tumorigenesis. Phosphorylation of Nrf2 in the
Neh6 domain (Figure 1) catalysed by Gsk-3 creates a phosphodegron that recruits β-TrCP.
β-TrCP interacts with the Skp1 E3 adaptor protein, part of the Skp1-Cul1-Rbx1 core E3
complex, which ubiquitinates Nrf2 tagging it for degradation. Two regions within the Nrf2
Neh6 region have been identified as highly conserved and are responsible for binding to
β-TrCP. One site, located at the N-terminal of Neh6, called Sds1, contains a putative DSGIS
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non-canonical β-TrCP-binding site. The second, Sds2, is located in the C-terminal portion
of Neh6 [44].
Nrf2 activity is also regulated by the autophagy pathway through p62 (SQSTM1). p62
competes with the DLG motif of Nrf2 [31] to binds Keap1 preventing ubiquitination of the
transcription factor [12]. This pathway is regulated by post-translational modifications in
which p62 is phosphorylated and ubiquitinated in order to compete with Nrf2 for Keap1
binding. SQSTM1 is activated under stress conditions acting as a scaffold protein within
protein complexes to enhance signalling in DNA transcription and cell survival. It is hy-
pothesised that p62 acts as an adaptor protein for selective autophagy, the selective removal
of cellular components such as protein aggregates. p62 is activated when selected damaged
components are tagged for autophagy via ubiquitination. p62 recognises ubiquitin-tags
and assembles onto the complex along with other core autophagy proteins. This results
in activation of early autophagosome biogenesis. During this process, p62 is phosphory-
lated, resulting in the destabilisation of p62 dimers. This increases the binding affinity of
p62 to the ubiquitin-tagged target protein. Keap1 binds to p62 via a Keap1-interacting
region (KIR), resulting in Keap1 being sequestered with the ubiquitin-tagged target protein
complex, allowing the release of Nrf2 and subsequent activation. The tagged components,
phosphorylated p62 and Keap1 become degraded by autophagy [12]. Furthermore, im-
paired autophagy can lead to increased oxidative stress, the subsequent accumulation of
p62 and further upregulation of Nrf2.
Additional control of Nrf2 occurs in the nucleus to regulate its cellular localisation.
These regulators include the Src subfamily A proteins, Fyn, Src, Yes and Fgr proteins that
phosphorylate Nrf2 at tyrosine position 568 [45]. Phosphorylation at this site triggers Nrf2
nuclear export and subsequent cytosolic degradation to prevent prolonged permissive tran-
scription. However, upon oxidative stress, these negative regulators are phosphorylated
and exported out of the nucleus to maintain Nrf2 in the nucleus.
3. Nrf2 in the Nucleus
Upon activation, e.g., repression of degradation, the newly synthesised Nrf2 molecules
can translocate into the nucleus where they activate transcription of a large array of
genes. In this section, we will focus on the basic principles underlying Nrf2-dependent
transcription.
3.1. Nrf2 Target Genes
Nrf2 is a transcription factor belonging to the large basic region-leucine zipper (bZIP)-
type family located in the Neh1 domain (Figure 1) [12]. Other members of this family in-
clude Jun, Fos, Bach1 and Maf proteins. This group of transcription factors is characterised
by a long α-helix. The N-terminal part contains basic residues that are responsible for DNA
binding and sequence specificity, the C-terminus contains several leucines responsible for
homo- and heterodimerisation. In fact, heterodimerisation across bZIP transcription factors
has been observed using coil-coiled arrays [46]. In addition, Nrf2 contains a conserved
stretch of residues at the N-terminal of the DNA binding domain referred to as CNC
(cap’n’collar) domain, which further contributes to sequence recognition.
The complex Nrf2 dependent signalling has been extensively studied. The pathway
can be activated by ROS [9] and autophagy through Keap1 phosphorylation [12] and by
Gsk3/β-TrCP [11]. It is, therefore, not surprising that Nrf2 is responsible for the expres-
sion of a large array of genes implicated in the oxidative stress response and glutathione
pathway, genes controlling cell proliferation and survival, metabolism, as well as proteins
involved in DNA repair, drug metabolising enzymes and transporters [13]. The develop-
ment of ChIP-seq techniques allowed the elucidation of the network of target genes. Using
either constitutive activation (Keap1−/−) or inhibition (Nrf2−/−), Malhorta et al. identified
basal and inducible target genes in mouse embryonic fibroblasts [47]. Chorley et al. used
a pharmacological approach to activate the pathway and have been able to identify with
high confidence new genes under the control of Nrf2 in lymphoid cells [48]. More recently,
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Namani et al. have been able to link Nrf2 to focal contact adhesion in cancer cells [49].
These studies clearly highlight that Nrf2 transcription is cell line and context dependent.
This is important if we consider overactivation of the pathway in cancer. A particularly
striking example is the ability of Nrf2 to bind enhancers of genes that are normally not
activated in non-transformed cells. Okazaki et al. demonstrated that Nrf2 was able to bind
the Notch3 enhancer, recruit co-activators (as highlighted by acetylated histone marks) and
activate transcription [50].
ChIP-seq experiments led to the determination of DNA sequences that Nrf2 preferen-
tially binds. They are referred to as CsMBE (CNC-sMaf binding element) or ARE/EpRE
(Antioxidant/Electrophile responsive element) [51] and are defined by (A/G)TGA(G/C)
nnnGCA. These sequences are most likely derived from the MARE sequence (Maf recogni-
tion element) that are recognised by Maf proteins.
3.2. Nrf2 and Its Partners Required for DNA Binding
Like other bZIP transcription factors, Nrf2 acts as a dimer. However, Nrf2 cannot
bind DNA as a homodimer: it requires its obligate partner sMaf [52]. sMafs (small mus-
culoaponeurotic fibrosarcoma) proteins are bZip transcription factors but they lack a
transactivation domain (Figure 1). In this respect, they are regarded as transcriptional
repressors [53]. There are three members (MafF, MafG and MafK) that can associate with
Nrf2 to initiate transcription (Figure 2). Although the heterodimerisation with Nrf2 has
been known for a long time, it has only recently been formally demonstrated. Using
a cell line deficient for the three sMafs, Katsuoka et al. observed no induction of Nrf2
dependent genes. However, ectopic expression of a tethered dimer Nrf2/sMafG could
restore transcription at Nrf2 target genes [54].
Interestingly, the consensus binding motif of sMaf (MARE: TGCTGACTCAGCA) and
CsMBE are similar. The question of understanding the recognition by sMaf homodimers
and sMaf/Nrf2 is important. Otsuki et al. proposed that Y502 in the Nrf2 DNA binding
domain is responsible for the discrimination. Indeed, Nrf2 Y502A failed to recognise the
CsMBE element while binding to the MARE sequence [51], explaining both the preferential
recruitment of Nrf2/sMaf at CsMBE sequences and prevention of binding at MARE motifs.
Beyond the traditional role of Nrf2 as a transcription activator, a recent publication
suggests that it can act as a repressor upon chemical activation and translocation into the
nucleus. Liu et al. could demonstrate that the presence of a motif, located at the 3′end of
the CsMBE in the MYLK promoter, recruits RPA1 that competes with sMaf to interact with
Nrf2. Following an in silico analysis, they identified more than 420 genes containing this
repressing sequence, including eEFSec that contributes to selenoprotein translation (see
Section 5.4 “Nrf2 Regulation and the Selenium Connection”) [55]. This finding requires
further investigation to understand the full spectrum of Nrf2 dependent transcription.
3.3. Nrf2, Bach1 and the HO-1 Axis
A well-established Nrf2 axis is related to the heme oxygenase pathway. Hemes are
important protein cofactors for oxygen transport and for electron transfer. In response to
oxidative stress, heme is released from protein partners to induce catalysis of free radicals,
acting as a pro-oxidant. Under normal cellular conditions free heme is catabolised by the
heme oxygenease-1 (HO-1) enzyme. Its expression is under the control of Nrf2/sMaf,
and another CNC-bZIP transcription factor Bach1. This third protein contains a BTB
domain, bZIP DNA binding domain and a cytoplasmic localisation signal (Figure 1).
Being a member of the CNC family, Bach1 binds the DNA with sMaf proteins although
a report suggested that it can homodimerise through its BTB domain [56]. Interestingly
the transactivation domain(s) of Bach1 has not been identified yet. In this respect, it is
often viewed as a repressor. In fact, Bach1/sMaf bind the HO-1 promoter and represses
transcription in the absence of oxidative stress or free hemes. However, Bach1 is able
to sense the presence of free hemes and to bind them [57]. This affects its DNA binding
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capability, leading to promoter derepression [58]. Bach1 is then exported from the nucleus
by Crm1 [59] where its degradation is mediated by Fbxo22 and Skp1-Cul1 [60].
Two recent publications demonstrated the role of Bach1 in lung cancer metastasis [60,61].
Two distinct laboratories demonstrated that activation of the Nrf2 pathway, either through
Keap1 loss or antioxidant treatment, led to stabilisation of Bach1. Although paradoxical at
first sight, because Bach1 inhibits Nrf2 transcription, this observation can be rationalised
by considering the role of HO-1. Nrf2 upregulates HO-1 that in turn degrades free hemes,
their absence leads to Bach1 stabilisation by inhibiting its degradation. Surprisingly,
Lignitto et al. and Wiel et al. observed upregulation of pro-metastatic genes under the
control of Bach1, suggesting that the previously thought repressor possesses its own
transcriptional program. Wiel et al. could demonstrate that Bach1 can activate expression
of Glyceraldehyde 3-phophate dehydrogenase (GAPDH) and hexokinase 2 (HK2), two
proteins implicated in glucose metabolism, and is able to promote metastasis. These data
illustrate that the interplay between Nrf2 and Bach1 is by far more complex than a simple
activator/repressor model.
These data also open up the possibility of new cancer therapies: downregulation of
Nrf2 represents a seductive approach to target cancer cells, and conversely, inhibition of
Bach1 can decrease metastasis [60,61]. This is particularly relevant considering that the
Nrf2 pathway is deregulated in cancer.
4. The Role of Nrf2 in Cancer
The development of cancer is defined by six biological abilities gained by a cell in
order to break away from normal cellular behaviour and lead to tumour establishment.
These are the ‘hallmarks of cancer’ as defined by Hanahan and Weinberg [62,63]. These
include sustaining proliferative signalling, evading growth suppressors, resisting cell
death, enabling replicative immortality, inducing angiogenesis and activating invasion
and metastasis, the detachment of cells from the extracellular matrix (ECM). Furthermore,
the process of metastasis has been isolated as a separate process defined as the ability for
motility, invasion, colonisation and plasticity [64]. The constitutive expression of certain
transcription factors enables cancer cells to gain these abilities. Just like organisms, cancer
is highly complex and multi-layered which relies on a network of interactions at cellular,
tissular and organismic levels [65]. The ability to break away from a primary tumour via
metastasis to form multiple tumours in geographically separated tissues truly highlights
its extensiveness. Cancer achieves this by interacting with multiple body systems [65].
It is often described as a systemic disease whereby the tumour-body interaction results
in the primary tumour colonising host organs by expressing several factors including
transcription factors.
Transcription factors are commonly found to be up- or downregulated in the patho-
genesis of cancers [66]. Cancer arises when a cell begins to proliferate abnormally as a result
of genetic mutations that provide survival advantages to the cancerous cell. Mutations
that are advantageous to cancer development occur predominately in two types of genes:
proto-oncogenes which act as accelerators of cell cycle progression and tumour suppressor
genes, which slow cellular growth. Oncogenic mutations result in a gain of function and
it is estimated that about 20% of these mutations occur in transcription factor genes [67].
Tumour suppressor mutations result in a loss of function ultimately removing the barriers
on cellular growth which results in uncontrolled cell division. The most widely studied
tumour suppressor is the p53 transcription factor found mutated in 50% of cancers [68].
In addition, cancer cells require rewiring of the cellular metabolic pathways to provide
energy and intermediates for the cancer cell to survive and thrive. Cancer cells can become
vulnerable to cellular stress due to the high demand for rapid proliferation. High levels
of toxic metabolic by-products, including ROS, which normal cells manage in order to
maintain homeostasis, become an even more prominent issue with respect to the cancer
cell viability. Therefore, cancer cells do not only upregulate proteins for growth, but also
proteins required to control the detrimental by-products that come along with these advan-
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tages. It is therefore unsurprising that a prominent genetic target for cancer progression are
transcription factors essential for the highly conserved signal transduction pathways. These
transcription factors have become increasingly attractive targets for cancer therapy [67].
4.1. Nrf2, a Tumour Suppressor and an Oncogene
Nrf2 was originally considered as a tumour suppressor gene where a loss of function
mutation aided cancer progression. Under normal cellular conditions, Nrf2 is activated
within the local micro-environment in response to oxidative stress and other harmful
cues. In this respect, the cytoprotective Nrf2 target genes efficiently protect cells against
intracellular and external stresses: Nrf2 can be considered as a tumour suppressor [22].
The cytoprotective role of Nrf2 requires tight regulation and rapid inactivation to
avoid deleterious side effects. Recent studies have demonstrated that Nrf2 is found hyper-
activated in malignant cells with gain of function mutations resulting in survival advan-
tages to cancer cells because the same cytoprotective genes can favour tumour growth and
metastasis. Cancer cells, characterised by higher ROS levels, often show constitutive Nrf2
activation. This ultimately promotes oncogenesis by protecting tumours against oxidative
stress, chemotherapeutic agents and radiotherapy [13,22,69,70]. In this respect, Nrf2 can
also be considered as an oncogene.
4.2. Nrf2 Pathway Is Constitutively Activated in Cancer
Cancer cells require robust ROS detoxification, it is perhaps not surprising to observe
genetic mutations leading to constitutive activation of the Nrf2 pathway. This is particu-
larly true for the regulator Keap1. The majority of mutations in Nrf2 and Keap1 identified
have been found in a lung cancer background [71]. About 30% of non-small-cell lung
cancer (NSCLCs) show an increase in the expression of antioxidant genes, including Nrf2,
or inactivation of negative regulators, including Keap1. Nrf2 mutations are prominent
occurrences in other types of lung cancer: it is mutated in 30% lung squamous cell carci-
noma (LUSC) and in 25% lung adenocarcinoma (LUAC) as well as other squamous cell
carcinomas. Hyper-activation of Nrf2 is associated with the worst clinical prognosis of
lung cancer, highlighting it as an essential target for therapeutics in research. Furthermore,
Keap1 genetic mutations have been found in 25–30% of lung cancer patients with 41% of
these cases having a loss of function mutation [72]. Mutations in Keap1 that result in the
stability and increased activity of Nrf2 reside within the Kelch-like repeat domain signifi-
cantly reducing its binding to Nrf2 (Figures 1 and 2). This reduces the ability of Keap1 to
repress Nrf2 and this subsequently increases Nrf2-dependent transcription. In Nrf2, gain
of function mutations are predominantly clustered in the Neh2 domain, responsible for
Nrf2 regulation through interactions with the Keap1 regulator. Therefore, mutations that
reduce the ability of Nrf2-Keap1 interactions result in the constitutive activation of Nrf2
and are advantageous to cancer cells [73]. It is hypothesised that Nrf2/Keap1 mutations
are prominent in lung cancer because hyper-activation of Nrf2 signalling can be beneficial
to lung cells constantly exposed to oxygen and chemicals from the air. Therefore, mutations
that allow these cells to more readily cope with oxidative stress are not only beneficial to
normal lung cells but also malignant cells [74].
Nrf2 is also found mutated in liver cancer with mutations found in 6.2% of hepa-
tocellular carcinoma patients (HCC), the third biggest cause of cancer-related mortality
worldwide. All mutations were found in the DLG and ETGE ‘hotspot’ motifs [75]. Little is
known about the role of mutations in the Nrf2/ Keap1 pathway in the development of liver
cancer due to the limited research on the development of HCC. All mutations impair Nrf2-
Keap1 binding and therefore are characterised as activating mutations. However, a high
frequency of Nrf2 mutations in the early steps of hepatocarcinogenesis suggests Nrf2 may
be a prominent driver in the onset of HCC [76]. Furthermore, it has been recently shown
that the development of HCC due to inactivation of Keap1 also relies on the activity of
fructosamine-3-kinase (FN3K), which triggers de-glycation of Nrf2. When FN3K is absent,
Nrf2 is extensively glycated leading to instability and an inability to interact with small
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Maf proteins required for transcriptional activation, ultimately providing an advantage to
the cancerous cell [77]. This again highlights the great interest of Nrf2 in cancer therapy.
Mutations that target the Nrf2/Keap1 regulatory pathway are not just associated
with lung and liver cancer. Keap1 mutations that prevent ubiquitination of Nrf2 have also
been associated with breast, gastric, colorectal, prostate, gallbladder and ovarian cancers.
Additionally, mutations in the Neh2 domain of Nrf2 have been associated with head and
neck cancers, larynx, oesophagus and skin carcinomas.
As well as genetic mutations, Nrf2 hyper-activation in cancer can also arise as a result
of epigenetic modifications of Keap1 [78]. Accumulation of Nrf2 can arise due to the
inability of Keap1 to form stable interactions with Nrf2. One such example is the hyper-
methylation of the Keap1 gene preventing its expression in lung, prostate and colorectal
cancers [78,79]. Targeting the epigenetic modifications has been considered a novel strategy
to increase sensitivity to anticancer drugs because of the link between the deregulation of
the Nrf2 pathway with chemo-resistance.
In addition to disruption of the regulation by Keap1, Nrf2 has also been associated
with carcinogenesis by interacting with proteins implicated in cancer. These proteins
activate the Nrf2 pathway resulting in its constitutive activation and providing a growth
advantage to malignant cells. One example is the p21 protein essential in cell-cycle arrest
and oxidative stress response [80]. p21 competes with Keap1 for binding to Nrf2, stabilising
and activating Nrf2. Over-expression of p21 therefore out competes Keap1 resulting in
increased levels of active Nrf2 [81].
Predominant regulation of Nrf2 occurs at the protein level. However, Nrf2 transcrip-
tion can also be increased by activated oncogenes including KRAS, BRAF and c-MYC.
Therefore, Nrf2 is also described as an essential mediator of oncogenesis acting down-
stream of many oncogenes. The role of Nrf2 in cancer development makes it an interesting
factor for therapeutic targeting.
Cancer cells, being exposed to higher ROS levels than their healthy counterpart, leads
to a constitute activation of the Nrf2 pathway. An adverse effect is the expression of
anti-apoptotic factors that prevent cell death programs.
5. Nrf2 and the Cell Death Programs
Upon oxidative stress, Nrf2 activates the transcription of a large array of genes, in-
cluding proteins involved in the thioredoxin [82] and glutathione systems [83,84]. These
two systems rely on the presence of selenocysteine in the active sites of key enzymes [85].
They contribute to reduce the oxidative stress and inhibit programmed cell death. Under-
standing how Nrf2 contributes to evade them could constitute a strategy to treat cancer
patients.
5.1. Detoxifying Enzymes and Cancer
Selenium is a trace element that is present in organisms as low molecular weight
selenocompounds [86] and can be used as modified amino acids in proteins. Selenoproteins
designate a class of proteins containing either selenomethiones (SeMet) or selenocysteines
(SeCys). Selenium can be incorporated into SeMet as a function of its availability in the
diet, and be used to synthetise selenomethionine-proteins. It can be catabolised in the
liver to form inorganic compounds (selenate and selenide). These latter forms can be
actively used by our body to incorporate selenocysteines into proteins. Considering that
selenium is present at trace levels, we have evolved pathways to tune the expression of
seleno-containing proteins depending on the needs and the availability of selenium. This
gives rise to the so-called “selenoprotein hierarchy” [87].
Selenocysteines are analogs of cysteines, with the exception that the Sulphur atom is
replaced by a selenium. One of the consequences is higher nucleophilic properties, lower
pKa and reduction potential that make SeCys containing proteins particularly reactive.
Although some of the selenoproteins do not have known functions, most of them are
involved in detoxification. The well characterised glutathione peroxidase (GPx) and
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thioredoxin reductase (TrxR) families are two examples of seleno-containing enzymes
having antioxidant properties. We invite the readers to consult two comprehensive reviews
for further details on seleno-containing proteins and their functions [23,85]. The GPx family
catalyses the reduction of oxidised substrates, including H2O2 and oxidised lipids. The
TrxR family is involved in the recycling of oxidised thioredoxin that has been used to
reduce oxidised proteins (Figure 3).
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Possessing antioxidant functions, selenoproteins expression is intrinsically linked
to the redox state. In fact, hydrogen peroxide treatment of HEK293 cells increases the
expression of GPx1, GPx4 and TrxR1 as well as other selenoproteins [88]. Similarly, se-
lenium deficiency is able to activate the Nrf2 pathway. Micro-array experiments on the
intestinal cells of mice that were fed with a low Se diet demonstrate increased expression
of 48 Nrf2 dependent genes, including antioxidants and phase II detoxifying enzymes, as
well as increased mRNA levels of selenoproteins [89]. However this seems to be tissue
specific since hepatoma cells (HepG2) do not display major changes in Nrf2 activation
under selenium deficiency or supplementation [90]. We invite the reader to consult the
comprehensive review from Brigelius-Flohe and Kipp [91] and Arnér [92] for more details
on the crosstalk between seleno-containing detoxifying enzymes and the Nrf2 pathway.
The role of selenoproteins in cancer and metastasis has been demonstrated at different
levels. The thioredoxin reductase family is generally overexpressed in cancer [93], and is
correlated with poor prognosis [94]. In fact, TrxR1 is required for tumorigenesis [95]. On
the contrary GPx1 expression is decreased in cancer [96], and its ectopic overexpression
reduces pancreatic tumour growth both in vitro and in vivo [97]. GPx2 null mice have a
higher incidence of colon tumours than wild type mice [98]. This may be due to the loss of
anti-inflammatory effects of GPx2 [99]. On the contrary, the selenoprotein is overexpressed
in non-inflammatory intestinal cancer [100]. Decreased expression of the secreted GPx3 has
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been correlated with poor prognosis in patients with prostate cancer [101]. Loss of GPx4,
involved in lipid reduction, sensitises cancer cells to ferroptosis [102] (see below). The
roles of detoxifying enzymes, and selenoproteins in a larger sense, in cancer are complex.
In this respect, we recommend the readers interested in this aspect to consult two recent
comprehensive reviews [103,104].
The crucial role played by detoxifying enzymes in maintaining the redox homeostasis
is highlighted by cell death programs associated with their regulation.
5.2. Nrf2, GPx4 and Ferroptosis
Ferroptosis is a newly identified type of regulated cell death, which is independent
of caspase activity [105] and is characterised by higher levels of lipid peroxidation. Lipid
peroxidation is particularly harmful for cells because it threatens (i) the assembly, structure
and dynamics of membranes and (ii) can further enhance the ROS levels through Fenton
reaction [106]. Cells rely on a complex machinery to detect lipids peroxidation and their
reduction. The selenoprotein glutathione perodixase 4 (GPx4) is particularly important in
that aspect: the protein catalyses the reduction of oxidised lipids using glutathione as an
electron donor. The oxidised glutathione is then recycled by a glutathione reductase using
NADPH (Figure 3). If either the glutathione biogenesis pathway or GPx4 is compromised,
ferroptosis can be triggered [107]. Considering that GPx4 is a bona fide target gene of Nrf2,
either directly or indirectly, several links between ferroptosis and the Nrf2 pathway have
been proposed. We would like to direct the reader to a recent review for more details [108].
Of particular interest, Takahashi et al. [109] recently used CRISPR-Cas9 screens to
identify genes required by Nrf2 hyperactivation to sustain cell proliferation in 3D spheroids.
This culture technique recapitulates the gradients naturally occurring in tumour (nutrients,
oxygen, metabolism [110]). Using lung cancer cell lines (A549 and H1347), they demon-
strated that Nrf2 inhibition by shRNA reduces cellular proliferation more significantly in
3D than in conventional cell culture. Importantly, Nrf2 knockdown decreases cell prolif-
eration at the early stage, and clearance of the inner core at the later stages. Conversely
the authors also demonstrated that Nrf2 activation increases cell survival of the inner core
through ferroptosis prevention. In fact, knocking down both Nrf2 and GPx4 was more
lethal in both A549 and H1347 spheroids than 2D.
It is now clear that tumours require inhibition of ferroptosis to sustain prolifera-
tion [111]. Inhibition of both the Nrf2 pathway and GPx4 activity (or glutathione pathway)
is an attractive strategy to specifically target cancer cells.
5.3. Nrf2, TrxR1 and Apoptosis
Nrf2 is responsible for the expression of thioredoxin reductase 1 (TrxR1). TrxR1 is
part of the thioredoxin system. Thioredoxins are small proteins that catalyse the reduction
of proteins by cysteine thiol-disulfide exchange. TrxR1 activity is necessary to recycle
thioredoxin (Trx) [25]. The electrons from NADPH are transferred to an oxidised Trx in
several steps: first through FAD then to a disulfide bond in the N-terminal domain of
molecule A. They are then transferred to a second site located at the C-terminal part of
molecule B that contains a selenylsulfide (Se-S) covalent bond. The selenothiol can then
reduce oxidised Trx to recycle the molecule (Figure 3). The presence of a selenothiol group
is of utmost importance for the correct activity of TrxR1.
As recently noted by Arner [112], the role of TrxR1 is complex in cancer, but com-
pounds targeting the selenocysteine in TrxR1 have been developed and demonstrated
reduction in cancer cell viability both in vitro and in mouse models [113,114].
Compounds modifying the selenocysteine in TrxR1 are thought to transform the
detoxifying enzyme into a pro-oxidant protein. The term used by Anestal et al. is SecTRAPs
for selenium compromised thioredoxin reductase-deprived apoptotic proteins. Under
conditions where the selenocysteines are compromised, either by nucleophile reaction or
truncation, SecTRAPs can still utilise NADPH to reduce FAD but the electron transfer
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to Trx is interrupted. It results in production of ROS in a feed forward mechanism that
ultimately leads to apoptosis [115,116].
It appears that the presence of selenocysteines in both GPx4 and TrxR1 is necessary to
sustain detoxification [115–117] and prevent triggering of cell death programs.
5.4. Nrf2 Regulation and the Selenium Connection
Nrf2 couples expression of the phase II detoxifying enzymes, including GPx4 and
TrxR1, with expression of anti-apoptotic factors [118]. It seems paradoxical to observe cell
death programs triggered even under Nrf2 activation. It is therefore important to under-
stand how cell ferroptosis and apoptosis are triggered in a healthy context. This knowledge
could potentially be applied to target cancer cells that often show Nrf2 activation and
inhibition of ROS-related cell death programs. In the next paragraphs, we will discuss the
possible mechanisms underlying the control of programmed cell death in heathy cells and
how they are deregulated in cancer.
The selenocysteines are encoded by the UGA stop codon. Cells rely on a specific
machinery to properly insert these residues during translation. A specific stem-loop on
the mRNA, called SECIS element, is recognised by SBP2 that in turn recruits eEFsec
(selenocysteine-specific elongation factor). eEFsec also binds the SeCys tRNA and ensures
efficient incorporation of the amino acid into the selenoproteins [85].
Importantly, depletion of SBP2 or eEFSec leads to lower levels of GPx4 [119]. Fur-
thermore, Papp et al. demonstrated that SBP2 knockdown increases ROS levels and
apoptosis [120]. This highlights that defects in the selenocysteine pathway have tremen-
dous effects on the synthesis of detoxifying enzymes, and ultimately the oxidative stress
response and cell survival.
A recent report suggests that the SeCys tRNA transcription is under a redox control.
The authors provided a model explaining the crosstalk between Nrf2 activation and redox
control of the detoxifying enzyme translation [121]. Transcription of the SeCys tRNA is
achieved by the RNA polymerase III, which is responsible for the expression of all the short
and untranslated RNA, including the entire pool of tRNA. More specifically, the SeCys
tRNAs are transcribed at the type 3 promoters in metazoans [122]. These promoters are
markedly different from the type 1 and 2 in their architecture and requirement of specific
transcription factors [123]. Recruitment of the RNA Polymerase III relies on TFIIIB, a core
transcription factor composed of three subunits: (i) TBP, (ii) Bdp1 [124], and (iii) Brf2 (B-
related factor 2). Recent studies have highlighted a direct link between Brf2 over-expression
and many types of cancer, including lung [125,126] and breast cancer [127,128]. The crystal
structure of Brf2 in complex with TBP and the DNA revealed the presence of a conserved
cysteine interacting with DNA [121]. Gouge et al. demonstrated that, under oxidative
conditions, the cysteine can be oxidised and abrogates Brf2 binding on the DNA. This neg-
atively regulates the RNA polymerase III recruitment specifically at the type 3 promoters,
thereby modulating the transcriptional output, including the SeCys tRNA. Gouge et al.
could demonstrate that the lack of SeCys tRNA availability combined with its relative
short half-life [129] contributes to the regulation the selenoproteins levels, including GPx4.
In fact, it was proposed that under prolonged oxidative conditions, the SeCys tRNAs be-
come the limiting factor in the selenoprotein translation: the authors observed appearance
of truncated forms of selenoproteins upon sustained oxidative treatment. As expected,
the truncated detoxifying enzymes triggered apoptosis in healthy cells. Conversely, Brf2
knockdown in A459 cancer cells, in which the Nrf2 pathway is overactivated and Brf2
overexpressed, leads to cell death. They proposed that Brf2 acts as a master switch in the
oxidative stress response by regulating in a redox dependent manner the levels of SeCys
tRNA. This safety mechanism is by-passed in cancer: by overexpressing Brf2, cancer cells
alleviate this regulation and prevent apoptosis. Importantly, this phenomenon occurs even
in the presence of activated Nrf2 [130] (Figure 4).
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In light of the growing body of evidence linking GPx4 deficiency and ferroptosis,
the role of Brf2 in this particular pathway needs to be clarified, especially in 3D spheroid
cultures. In a broader context, triggering one cell death pathway over the other (apoptosis
versus ferroptosis) remains an open question but it is likely to involve a feedforward mech-
anism. Under prolonged oxidative levels, appearance of truncated detoxifying enzymes
could lead to further increased ROS levels. Under high oxidative conditions, Nrf2 can
express the transcription factor Kruppel-like factor 9 (Klf9) [131]. In turn, accumulation of
Klf9 in the nucleus suppresses the expression of TrxR2, which further increases ROS levels.
Zucker et al. demonstrated that this is sufficient to trigger apoptosis [131]. Considering
that the cell programs can be triggered by different compromised detoxifying enzymes
(GPx4 and SecTRAPs), it is possible that the preferential activation of one pathway over
the other might be linked to their expression levels in different tissues and cell types, as
well as their position in the “selenoprotein hierarchy”. In addition, a possible crosstalk
between SecTRAPs and ferroptosis is also possible, as high doses of auranofin, an inhibitor
of TrxR family, can induce ferroptosis in mice liver [132]. Further research on the conditions
leading to ferroptosis or apoptosis is required to explain their preferential activation.
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6. Conclusions
Nrf2 possesses undoubtedly beneficial roles in cancer prevention by activating the
ROS detoxification machinery, antiapoptotic genes, xenobiotic metabolising enzymes,
and transporters. This pathway requires tight control because, upon deregulation, it
promotes metastasis and tumour growth, ultimately threatening cancer patient survival.
Deregulation of Nrf2 in cancer can arise from several causes: from inherent higher ROS
levels, to point mutations and promoter silencing. This leads to apoptosis and ferroptosis
prevention. In this respect, efforts to develop small molecules modulating the Nrf2 pathway
have been ongoing for the last few years, and the focus has recently shifted from activating
to inhibiting the pathway [133]. However, one would expect side effects associated with
modulators of the oxidative stress response. A possible strategy would be to re-activate
the cell death programs or use a combination of drugs targeting both the Nrf2 pathway
and the detoxification machinery. Obtaining high resolution structures along the Nrf2
pathway, deepening understanding of Nrf2 crosstalk with the transcriptional machinery,
and characterisation of the cell death programs would, hopefully, allow more targeted
cancer therapies. Detoxifying enzymes containing a catalytic selenocysteine are regulated
by and regulate ROS levels. Taking into account that they possess the ability to trigger cell
death programs when they are compromised, cancer cells need to by-pass this regulation
by overexpressing them and/or sustaining SeCys tRNA levels. Future research might also
concentrate on further characterising the functions of seleno-containing proteins and their
intricate relationship with the Nrf2 pathway. This would allow for the development of
therapies for the benefit of cancer patients.
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